% alzhub.org library filter % Source: https://alzhub.org/research?author=Salloway+S&design=trial % 12 entries, in the order the page lists them. Built from alzhub.org's own records. % 0 entries have no readable author in the source record and carry no author field. @article{salloway2025-40390253, author = {Salloway, S. and Pain, A. and Lee, E. and Papka, M. and Ferguson, M. B. and Wang, H. and Hu, H. and Lu, M. and others}, title = {{TRAILBLAZER-ALZ 4: A phase 3 trial comparing donanemab with aducanumab on amyloid plaque clearance in early, symptomatic Alzheimer's disease}}, journal = {Alzheimer's \& dementia : the journal of the Alzheimer's Association}, year = {2025}, doi = {10.1002/alz.70293}, pmid = {40390253}, url = {https://doi.org/10.1002/alz.70293} } @article{salloway2014-24450891, author = {Salloway, S. and Sperling, R. and Fox, N. C. and Blennow, K. and Klunk, W. and Raskind, M. and Sabbagh, M. and Honig, L. S. and others}, title = {{Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease}}, journal = {The New England journal of medicine}, year = {2014}, doi = {10.1056/nejmoa1304839}, pmid = {24450891}, url = {https://doi.org/10.1056/nejmoa1304839} } @article{salloway2022-34807243, author = {Salloway, S. and Chalkias, S. and Barkhof, F. and Burkett, P. and Barakos, J. and Purcell, D. and Suhy, J. and Forrestal, F. and others}, title = {{Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease}}, journal = {JAMA neurology}, year = {2022}, doi = {10.1001/jamaneurol.2021.4161}, pmid = {34807243}, url = {https://doi.org/10.1001/jamaneurol.2021.4161} } @article{bateman2023-37966285, author = {Bateman, R. J. and Smith, J. and Donohue, M. C. and Delmar, P. and Abbas, R. and Salloway, S. and Wojtowicz, J. and Blennow, K. and others}, title = {{Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease}}, journal = {The New England journal of medicine}, year = {2023}, doi = {10.1056/nejmoa2304430}, pmid = {37966285}, url = {https://doi.org/10.1056/nejmoa2304430} } @article{salloway2025-39556389, author = {Salloway, S. and Wojtowicz, J. and Voyle, N. and Lane, C. A. and Klein, G. and Lyons, M. and Rossomanno, S. and Mazzo, F. and others}, title = {{Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease}}, journal = {JAMA neurology}, year = {2025}, doi = {10.1001/jamaneurol.2024.3937}, pmid = {39556389}, url = {https://doi.org/10.1001/jamaneurol.2024.3937} } @article{salloway2018-30129411, author = {Salloway, S. and Marshall, G. A. and Lu, M. and Brashear, H. R.}, title = {{Long-Term Safety and Efficacy of Bapineuzumab in Patients with Mild-to-Moderate Alzheimer's Disease: A Phase 2, Open-Label Extension Study}}, journal = {Current Alzheimer research}, year = {2018}, doi = {10.2174/1567205015666180821114813}, pmid = {30129411}, url = {https://doi.org/10.2174/1567205015666180821114813} } @article{sims2023-9857475c, author = {Sims, JR. and Zimmer, J. A. and Evans, C. D. and Lu, M. and Ardayfio, P. and Sparks, J. and Wessels, A. M. and Shcherbinin, S. and Wang, H. and Monkul Nery, E. S. and Collins, E. C. and Solomon, P. and Salloway, S. and Apostolova, L. G. and Hansson, O. and Ritchie, C. and Brooks, D. A. and Mintun, M. and Skovronsky, D. M. and {TRAILBLAZER-ALZ 2 Investigators}}, title = {{Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial}}, journal = {JAMA}, year = {2023}, pmid = {37459141} } @article{salloway2009-19923550, author = {Salloway, S. and Sperling, R. and Gilman, S. and Fox, N. C. and Blennow, K. and Raskind, M. and Sabbagh, M. and Honig, L. S. and others}, title = {{A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease}}, journal = {Neurology}, year = {2009}, doi = {10.1212/wnl.0b013e3181c67808}, pmid = {19923550}, url = {https://doi.org/10.1212/wnl.0b013e3181c67808} } @article{coric2012-22892585, author = {Coric, V. and van Dyck, C. H. and Salloway, S. and Andreasen, N. and Brody, M. and Richter, R. W. and Soininen, H. and Thein, S. and others}, title = {{Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease}}, journal = {Archives of neurology}, year = {2012}, doi = {10.1001/archneurol.2012.2194}, pmid = {22892585}, url = {https://doi.org/10.1001/archneurol.2012.2194} } @article{salloway2011-21917766, author = {Salloway, S. and Sperling, R. and Keren, R. and Porsteinsson, A. P. and van Dyck, C. H. and Tariot, P. N. and Gilman, S. and Arnold, D. and others}, title = {{A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease}}, journal = {Neurology}, year = {2011}, doi = {10.1212/wnl.0b013e3182309fa5}, pmid = {21917766}, url = {https://doi.org/10.1212/wnl.0b013e3182309fa5} } @article{blennow2012-22473769, author = {Blennow, K. and Zetterberg, H. and Rinne, J. O. and Salloway, S. and Wei, J. and Black, R. and Grundman, M. and Liu, E. and others}, title = {{Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease}}, journal = {Archives of neurology}, year = {2012}, doi = {10.1001/archneurol.2012.90}, pmid = {22473769}, url = {https://doi.org/10.1001/archneurol.2012.90} } @article{sperling2012-22305802, author = {Sperling, R. and Salloway, S. and Brooks, D. J. and Tampieri, D. and Barakos, J. and Fox, N. C. and Raskind, M. and Sabbagh, M. and others}, title = {{Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis}}, journal = {The Lancet. Neurology}, year = {2012}, doi = {10.1016/s1474-4422(12)70015-7}, pmid = {22305802}, url = {https://doi.org/10.1016/s1474-4422(12)70015-7} }